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Micro-CTPolycythemia vera (PV) is a myeloproliferative disorder involving hematopoietic stem cells. A recurrent
somatic missense mutation in JAK2 (JAK2V617F) is thought to play a causal role in PV. Therefore, targeting
Jak2 will likely provide a molecular mechanism-based therapy for PV. To facilitate the development of such
new and speciﬁc therapeutics, a suitable and well-characterized preclinical animal model is essential.
Although several mouse models of PV have been reported, the spatiotemporal kinetics of PV formation and
progression has not been studied. To address this, we created a bone marrow transplant mouse model that
co-expresses mutant Jak2 and luciferase 2 (Luc2) genes. Bioluminescent imaging (BLI) was used to visualize
disease cells and analyze the kinetics of PV development in vivo. To better understand the molecular
mechanism of PV, we generated mice carrying a kinase inactive mutant Jak2 (Jak2K882E), demonstrating
that the PV disease was dependent on constitutive activation of the Jak2 kinase activity. We further showed
that the Jak2V617F mutation caused increased stem cell renewal activity and impaired cell differentiation,
which was at least in part due to deregulated transcriptional programming. The Jak2V617F–Luc2 PV mice
will be a useful preclinical model to characterize novel JAK2 inhibitors for the treatment of PV.
Published by Elsevier B.V.1. Introduction
Myeloproliferative diseases (MPDs) including polycythemia vera
(PV), essential thrombocytosis (ET) and primary myeloﬁbrosis (PMF)
are a group of diseases characterized by overproduction of terminally
differentiated cells [1–3]. Recently, a somatic mutation at amino acid
residue 617 in JAK2 (JAK2V617F) was discovered in approximately 99%
of PV patients and about 50% of ET andPMF patients [4,5]. Severalmouse
models over-expressing the mutant mouse Jak2 carrying the
corresponding mutation found in human MPD patients (Jak2V617F)
have been reported [4,6,7]. These mice develop elevated hematocrit
(HCT), erythrocytosis, extramedullary hematopoiesis and splenomegaly,
whichare characteristics of PV inhumans, therefore establishing a causal
role of the mutant JAK2V617F in PV. Furthermore, some of these mice
have been used as preclinical animal models of PV for the development
of small molecule inhibitors targeting JAK2 [8–11]. However, a
longitudinal analysis of the kinetics of development of PV in theseies, 33 Avenue Louis Pasteur,
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B.V.mouse models has not been reported. Moreover, although it was
assumed that the constitutively activated kinase activity of Jak2 is
important in exerting its function in causing thedisease by activating the
Jak2–Stat5 pathway, the underlyingmolecular mechanism has not been
fully understood. Toaddress these questions and toprovide an improved
preclinical model system, we developed a bone marrow transplant
mouse model by combining the expression of both Jak2V617F and
luciferase 2 genes (Luc2) in the mice. In this model, the transduced
disease cells co-express mutant Jak2V617F and Luc2, which allowed in
vivo visualization of disease burden in real time in living animals by
bioluminescence imaging(BLI). Using thismodel systemwewere able to
investigate the process of disease cell proliferation and trafﬁcking in the
mice over time aswell as analyze the endpoint when the disease is fully
established, thereby providing insight into the kinetics of the disease
development in this animal model. Moreover, we present evidence that
Jak2V617F mutation but not over-expression of the wild-type Jak2 can
perturb the transcriptional regulatory network, resulting in impaired
hematopoietic cell differentiation.
2. Materials and methods
2.1. Viral production
The mouse Jak2 cDNA was cloned into the MSCV–IRES EGFP
retroviral vector (a kind gift of Dr. Gary Gilliland). The V617F and
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site-directed mutagenesis kit (Quickchange-XL, Stratagene, La Jolla,
CA). The luciferase 2 cDNA was subcloned downstream of the Jak2
cDNA sequence by replacing the EGFP sequence in the same vector. All
the plasmids were conﬁrmed by restriction digestion and full-length
DNA sequencing. Retroviruses were produced by transfecting 293T
cells with the expression vector and packaging vector (pCL-Eco,
Imgenex, San Diego, CA) at a 1:1 ratio using FuGENE (Roche, Nutley,
NJ) following the manufacturer's protocol. The retroviral supernatant
was harvested after 48 h and the retroviral titer was determined by
transducing NIH3T3 cells with viral supernatant plus 10 μg/ml of
polybrene and analyzed either for the percentage of green ﬂuorescent
protein-positive (GFP+) cells by ﬂow cytometry (for GFP-containing
plasmids; FACSLSRII cytometer, BD Biosciences, San Jose, CA) or by
real-time PCR (for non-GFP-containing plasmids) 2 days after
transduction. The high titer viruses (5–10×106 U/ml) were used to
transduce bone marrow cells.
2.2. Bone marrow transplantation
Female C57Bl/6mice at age of 6–8weeks old were purchased from
Taconic (Germantown, NY). All procedures carried out on the animals
were reviewed and approved by the Institutional Animal Care and Use
Committee. The transplantation procedure was performed as previ-
ously described [6,12,13].
2.3. Histopathology
The spleen, liver and femur harvested from the mice were ﬁxed in
10% neutral-buffered formalin and embedded in parafﬁn. Standard
hematoxylin and eosin staining was performed on the spleen, liver
and decalciﬁed bonemarrow. Peripheral bloodwas collected by retro-
orbital bleeding and the blood smear was stained with Wright–
Giemsa. For immunohistochemistry (IHC) analysis, liver sections
were incubated in goat serum blocking solution with an antibody
speciﬁc for Ki67 (Neomarkers, Inc., Fremont, CA).
2.4. Micro-CT imaging
Mice were injected with 200 μl of Fenestra LC (ART, Canada) 30–
60 min prior to CT scan. Mice were anaesthetized with a continuous
ﬂow of 2–4% isoﬂurane/oxygen mixture (2.5 l/min) and whole body
was scanned using the eXplore Locus Ultra Pre-Clinical CT Scanner
(GE Healthcare, Ontario, Canada). CT images were analyzed using
Amira 4.1.1 software (Mercury Computer Systems, MA).
2.5. Bioluminescence imaging (BLI)
Mouse fur was removed and click beetle luciferin (Promega)
working solution was prepared in PBS at 30 mg/ml. The luciferin
was injected intraperitoneally (i.p.) at 150 mg/kg 10 min prior to
imaging. Mice were anaesthetized with a continuous ﬂow of 2–4%
isoﬂurane/oxygen mixture (2.5 l/min) using an induction chamber
XGI-8 gas anesthesia system (Caliper LifeSciences, Hopkinton, MA).
Imaging was performed using IVIS Spectrum system (Caliper
LifeSciences, Hopkinton, MA). The images were analyzed using
the LivingImage software 2.50 (Caliper LifeSciences, Hopkinton,
MA).
2.6. Tissue imaging
After in vivo imaging, mice were euthanized and tissues including
thymus, heart, lung, liver, spleen, stomach, intestine, kidney, long
bone and reproductive organs were quickly dissected and rinsed in
luciferin solution (150 μg/ml) for 2–3 min. Tissues were transferred
onto a black paper and imaged with IVIS Spectrum.2.7. Jak2V617F allele-speciﬁc real-time PCR
Genomic DNA from 30 μl of mouse peripheral blood was puriﬁed
by Qiagen tissue and blood DNA kit (Valencia, CA). Genomic DNA
(10 μg) was used for 10 μl real-time PCR reaction in 384-well plate
format using ABI 7900HT Real-Time PCR system (Foster City, CA). The
primers used in the PCR reactions are: Jak2cDNAF2, CACATAGGAAC-
TATTCAGAGTCTTTC; Jak2MutR3, AGAATGTTCTCCTCTCCACAGTA.
2.8. Western blot and IP Western blot analysis
Tissue or cell protein lysates were electrophoresed on SDS–PAGE
gels (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose
membranes. The membranes were subsequently blotted with anti-
bodies anti-pStat5 (1:500; Cell Signaling, Beverly, MA), anti-pJak2
(1:500; Cell Signaling), anti-Jak2 (1:1000; Millipore, Temecula, CA),
anti-Stat5 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), 4G10
(1:300; Millipore), anti-GATA-1 (1:500; Abcam, Cambridge, MA),
anti-PU.1 (1:500; Santa Cruz Biotechnology), anti-Sca1 (1:500; BD
Biosciences, San Jose, CA), anti-GAPDH (Quality Biological, Inc.,
Gaithersburg, MD), and anti-actin (Santa Cruz Biotechnology), and
the secondary antibody used was peroxidase-conjugated anti-rabbit
immunoglobulin (1:5000; Amersham Biosciences, Piscataway, NJ).
For IP Western blot analysis of pJak2, 50 mg of mouse spleen was
homogenized in 1 ml RIPA buffer, pre-cleared, and then incubated
with 10 μl of anti-pJak2 and 20 μl of Protein-A+G sepharose beads on
a rotator in cold room overnight. Samples were boiled in 50 μl 2×SDS
sample buffer and separated on 8% SDS–PAGE gel for 2 h and then
blotted with pan-phospho-tyrosine antibody 4G10.
2.9. Statistics
Values are represented as mean±SD and the data were analyzed
using two-tailed Student t test. Statistical signiﬁcance is reachedwhen
pb0.05.
3. Results
3.1. Jak2V617F–Luc2 bone marrow transplant mice develop
hallmarks of PV
Consistent with the previously reported Jak2V617F–GFP mice
[4,6,7], by 4 weeks after transplantation, Jak2V617F–Luc2 mice
developed elevated HCT and maintained this increased level of HCT
for at least 3 months. The complete peripheral blood counts also
showed increased RBC, Hb and WBC similar to the earlier reports
[4,6,7] (Supplementary Table 1). In contrast, Jak2WT–GFP, Jak2WT–
Luc2 and Jak2K882E–Luc2 mice had normal complete blood counts
and HCT (Fig. 1A) throughout the course of the study. Jak2V617F–
Luc2 mice also developed splenomegaly with enlarged spleen
volumes evident by micro-CT imaging (Fig. 1B). Splenomegaly was
conﬁrmed by directly weighing spleens harvested from the sacriﬁced
Jak2V617F–Luc2 mice (Fig. 1B and C). The bone marrow, spleen, liver
and peripheral blood samples were collected and subjected to
histopathological analysis. As shown in Fig. 2A, blood smears from
the Jak2V617F mice showed marked reticulocytosis. In contrast, the
blood smear from Jak2WT transplanted mice appeared normal. In the
bone marrow, while the Jak2WT mice showed normal marrow
architecture, the Jak2V617F mice exhibited increased erythrocytosis
andmaturingmyeloid cells. Histopathological analysis of the enlarged
spleen of the Jak2V617F mice revealed predominantly increased
differentiated erythroid cells, resulting in the expansion of red pulp
disrupting the white pulp architecture. Hyperplasia of erythroid
lineage cells was observed in the liver of Jak2V617F but not Jak2WT
mice. Increased cell proliferation was evidenced by strong Ki67
positive staining in the liver from Jak2V617F mice (Fig. 2B). Similar to
Fig. 1. Jak2V617F–Luc2 mice showed PV-like erythrocytosis and splenomegaly. (A) HCTs were measured 4 weeks after transplantation of cells expressing Jak2WT, Jak2K882E and
Jak2V617F. HCTs were elevated in bone marrow transplant mice expressing Jak2V617F. HCTs remained normal in Jak2WT and Jak2K882E control mice throughout the study. ⁎⁎
indicates highly signiﬁcant increase of HCTs in Jak2V617F mice compared to Jak2WT or Jak2K882E control mice (pb0.01). (B) μCT imaging was used to visualize and quantify the
spleen volumes in vivo. Purple, spleens. A representative image for each of the genotypes is shown on the top. Volumes measured by μCT and post-euthanasia spleen weights are
indicated below the images. The values are represented as mean±SD. Jak2V617F vs. Jak2WT: p=0.0138, spleen volumes; p=0.00001, spleen weight. (C) Gross images of spleens
isolated from Jak2WT and Jak2V617F transplanted mice showed consistent differences.
Fig. 2.Myeloid hyperplasia was seen in Jak2V617F transplanted mice. (A) Histopathology of myeloid hyperplasia in the bone marrow transplant mice. Tissues from Jak2V617F and
Jak2WT mice were collected at 1 month after transplantation and analyzed by H&E staining. Blood smears were stained with Giemsa. PB, peripheral blood; BM, bone marrow; W,
white pulp; R, red pulp; arrow, multiple small aggregates of immature erythroid and myelocytic cells. (B) Immunohistochemistry of Jak2V617F mutant and Jak2WT bone marrow
transplant mice. Livers were collected at 1month after transplantation and subjected to IHC staining with Ki67 antibody. The positive Ki67 staining in the perivascular and sinusoidal
regions in Jak2V617F mutant but not the wild-type mouse liver is consistent with extramedullary hematopoiesis in the mutant mice.
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logical abnormalities (data not shown).
3.2. Imaging of bone marrow reconstitution process and development of
PV after bone marrow transplantation
To visualize the processes of homing, proliferation and trafﬁcking
of transplanted cells, we imagedmice transplanted with bonemarrow
cells transduced with Jak2V617F–Luc2, Jak2K882E–Luc2 or Jak2WT–
Luc2 retroviruses at various time points after transplantation. The
transplanted cells rapidly distributed in the circulation and harbored
in several major organs within 1 h after transplantation. Strong
luciferase signals were observed in the lung and spleenwhile liver and
abdominal signals were evident but at a lower level compared to the
lung and spleen (Fig. 3A). After a rapid transient decline in BLI signals
at day 1, the transduced cells exponentially proliferated in the ﬁrst 2
weeks, especially in the spleen and bones such as tibia, femur,
vertebra and sternum, and reached a steady level between 8 and 14
days after transplantation after initial homing into the tissues (Fig. 3A
and B; Supplementary Fig. 1). In a separate experiment, we started
imaging 2 weeks after transplantation and also found that luciferase
signals had reached a steady level and were sustained over at leastFig. 3. Visualization of bone marrow reconstitution process in live animals. (A) Represent
marrow reconstitution indicated by BLI signals from the spleen as a function of the total lat
days after BMT showing a trend toward stronger signals in Jak2V617F than Jak2WTmice. How
of Jak2V617F–Luc2 cells. Mice were imaged 19 weeks after transplantation. Mice were eutha
10 min following luciferin injection. Tissues shown were dissected and rinsed in 15 μg/ml l
than Jak2WT and Jak2K882E mice.8 weeks (Fig. 3A and B and data not shown). Both Jak2V617F–Luc2
and Jak2WT–Luc2 cells initially had similar kinetics during the bone
marrow reconstitution process in terms of total lateral BLI signals,
though the signal in the Jak2V617F–Luc2 mice was slightly higher
than the Jak2WT–Luc2 mice (Fig. 3C) around 2 weeks after
transplantation. However, the difference was not statistically signif-
icant (pN0.05) at this early time point. Interestingly, this difference
continued to increase over time. By 19 weeks after transplant, a
signiﬁcantly stronger total lateral BLI signal was observed in
Jak2V617F–Luc2 than Jak2WT–Luc2 control mice (Supplementary
Fig. 2). The ratios of spleen signals over total lateral signals rapidly
increased during the ﬁrst 1–2 weeks from 15% to 80% for both
Jak2V617F–Luc2 and Jak2WT–Luc2 cells (Fig. 3B). Interestingly,
mutant Jak2V617F–Luc2 cells sustained high levels (70–80%) in
spleen from week 1 to at least week 5. In contrast, Jak2WT–Luc2
cells in spleen quickly declined as early as day 10 after transplantation
from 80% to 40% within 5 weeks. It is intriguing that BLI revealed
accumulation of labeled cells in the abdominal region over time,
which were subsequently conﬁrmed to reside in the intestine by
ex vivo post-laparotomy imaging (Fig. 3D). The precise underlying
mechanism for this observation is currently unknown. However,
the distribution of BLI signal in the gut in bone marrow transplantative BLI images at various time points in Jak2V617F–Luc2 mice. (B) Kinetics of bone
eral signals. ⁎, pb0.05; ⁎⁎, pb0.01, relative to Jak2WT mice. (C) BLI measurement at 14
ever, the difference was not statistically signiﬁcant (p=0.366). (D) Tissue distribution
nized using CO2 after luciferin injection and laparotomy imaging was then performed 5–
uciferin in PBS for 2–3 min and imaged. Stronger BLI signal was observed in Jak2V617F
Fig. 5. Pathway activation in Jak2V617F–Luc2 mice. (A) Mutant Jak2V617F induces
phosphorylation of Jak2 and Stat5 in vivo. (B) Differential regulation of GATA-1, PU.1
and Sca1 in Jak2V617F and Jak2WT cells. (C) A truncated pStat5 is present in spleens of
Jak2V617F but not Jak2WT mice. Both the full-length and truncated forms could be
induced by cytokines (6 ng/ml IL-3, 10 ng/ml IL-6 and 10 ng/ml stem cell factor;
StemCell Technologies) in Jak2V617F cells, whereas only the full-length form was
induced by cytokines in Jak2WT cells. Lane 1, Jak2WT; lane 2, Jak2WT+cytokines; lane
3, Jak2V617F; lane 4, Jak2V617F+cytokines. Mice were used 1 month after transplant.
Three independent experiments were performed and two mice/genotype were
analyzed in each.
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studies [14].
3.3. Quantiﬁcation of Jak2V617F mutant allele burden by real-time PCR
A Jak2 allele-speciﬁc real-time PCR assay was developed to
quantify the Jak2V617F allele burden in the peripheral blood from
bone marrow transplant mice. The Jak2V617F mutant allele level
increased within approximately the ﬁrst week and then exhibited a
trend toward decrease for about a week, though the decrease was not
statistically signiﬁcant. Interestingly, the allele increased signiﬁcantly
thereafter and the high level was maintained for at least 2 months
(Fig. 4).
3.4. Downstream pathway activation caused by Jak2V617F, but not
Jak2K882E in vivo
Spleens were harvested from Jak2V617F–Luc2, Jak2K882E–Luc2
and Jak2WT–Luc2 mice and protein was isolated from the spleno-
cytes. To dissect the Jak2–Stat5 pathway, we performed Western blot
and IP Western analysis using antibodies speciﬁc for the phosphor-
ylated forms of proteins. As shown in Fig. 5A, an elevated level of
pJak2 was detected in Jak2V617F compared to Jak2WT mice. The
Jak2K882E was expected to potentially have some dominant negative
effect. However, unexpectedly the pJak2 levels were similar between
the Jak2WT and Jak2K882E animals (data not shown). This could be
due to limitation of Western blot sensitivity that could not detect a
subtle reduction of pJak2 level. As we observed at 19 weeks after
transplant, the BLI signal was lower in the Jak2K882E relative to
Jak2WT mice (Supplementary Fig. 2), suggesting a possible effect of
Jak2K882E. The downstream effector of the Jak2 pathway, Stat5, was
also activated as evidenced by higher levels of pStat5 in the Jak2V617F
mice relative to the Jak2WT and Jak2K882E controls.
3.5. Jak2V617F-driven erythroid proliferation may be in part due to
enhanced stem cell renewal and deregulated cell differentiation
To better understand themolecularmechanism for the Jak2V617F-
driven PV, we determined the expression of several important
transcription factors known to be involved in hematopoietic stem
cell differentiation in the spleen where the increased erythropoiesis
appeared predominant. As shown in Fig. 5B, the erythroid cell
differentiation transcription factor GATA-1 [15–17] was only slightly
upregulated in splenocytes from Jak2V617F compared to Jak2WT
mice. In contrast, the myeloid cell differentiation transcription factor
PU.1 [18–20] was substantially downregulated in the Jak2 mutant
compared to the wild-type cells. Moreover, Sca1, a marker present inFig. 4. Quantiﬁcation of Jak2V617F allele burden. Amutant Jak2 allele-speciﬁc real-time
PCR assay was developed and used to quantify the Jak2V617F allele level in peripheral
blood of the bone marrow transplant mice. The mutant Jak2 allele level showed a trend
of decrease around 1–2 weeks after BMT, though it was not statistically signiﬁcant.
However, this mutant Jak2 allele level was rapidly followed by a substantial increase
and the elevated mutant allele level was maintained for at least 2 months.hematopoietic stem cells [21,22], was dramatically upregulated in the
Jak2V617F mutant cells, suggesting a possible defective differentia-
tion process in the Jak2V617F cells. Stat5 has been shown to play an
important role in stem cell renewal [23,24]. In the Jak2V617F–Luc2
mice, we observed elevated pStat5 in the bone marrow and spleens
compared to the Jak2WT–Luc2 mice (Fig. 5A), suggesting possible
increased stem cell renewal activity in the mutant mice. Interestingly,
in a Western assay using an antibody that recognizes the N-terminus
of the Stat5 protein, we found a shorter form of the Stat5 protein
present only in the Jak2V617F cells isolated from themutantmice, but
not in the Jak2WTmice (Fig. 5C). A truncated version of Stat5 has been
reported as a marker in undifferentiated cells and this truncated
protein was not detected in differentiated cells [25–27]. Consistent
with previous reports [6,7], we observed signiﬁcantly increased
erythroid progenitor cells in Jak2V617F than Jak2WT control mice
(Supplementary Fig. 3). Taken together, these results were in
agreement with the hypothesis that the cellular differentiation
process was impaired in the Jak2V617F cells.
4. Discussion
PV is a myeloproliferative disorder involving hematopoietic stem
cells, primarily affecting the erythroid lineage. A recurrent somatic
missense mutation in the pseudokinase domain of JAK2 (JAK2V617F)
is believed to play a causal role in PV [4,5]. Therefore, targeting Jak2
represents a novel molecular mechanism-based therapeutic approach
for PV. To facilitate development of a speciﬁc treatment for the
disease, we developed a bone marrow transplant mouse model in
which the transplanted cells co-express both the mutant Jak2 and
luciferase 2 (Luc2) genes. The luciferase reporter provides an internal
light source for in vivo bioluminescence imaging (BLI) to indicate the
number of cells and relative anatomical locations. This model system
allows us to investigate the spatiotemporal kinetics of bone marrow
reconstitution and PV development in the context of either wild-type
or mutant Jak2 in the transplanted mice. One of the advantages of this
1078 Y. Ma et al. / Biochimica et Biophysica Acta 1792 (2009) 1073–1079approach is that the non-invasive BLI modality allowed us to
repetitively image the same animals over time. Furthermore, such a
model system enabled us to better understand the mechanism,
development andmaintenance of PV. Thesemice will also be useful to
study the pharmacological properties of novel JAK2 inhibitors for the
treatment of PV.
Previous studies have shown that the hematopoietic stem cells
reside in several organs after bone marrow transplantation [28,29].
However, it is not known if the V617Fmutation in Jak2 has effect on the
initial homing and trafﬁcking of the donor cells after they are
intravenously injected into the recipientmice. To address this question,
we analyzed the BLI signal longitudinally at multiple time points in the
Jak2–Luc2 model system. Our results showed that although the initial
homing and distribution of the cells appeared to be similar between
Jak2V617Fand Jak2WTmice, thehigh level BLI signalwasmaintained in
the Jak2V617F mice, while the signal rapidly declined after a short
period of time in the Jak2WTmice. These observations suggest that the
Jak2V617F mutation may confer a survival advantage to the cells,
allowing their sustained renewal and conferring the ability to
repopulate after the initially injected mutant cells terminally differen-
tiated or died off in the mice. This is further supported by the allele-
speciﬁc PCR result in which similar kinetics of the Jak2V617F mutant
allele burdenwas observed. The kinetics of the allele level changes over
time is consistentwith theBLI result, suggesting that themoreprimitive
Jak2V617F cells repopulated the hematopoietic compartment, while
themore differentiated Jak2V617F cells completed their life cycle. Since
majority of the cells initially transplanted were more differentiated or
mature cells, which completed their life span and disappeared from the
circulation shortly after the transplantation, this caused the transient
decrease of the Jak2V617F allele and BLI level. However, as newly
differentiated cells were generated and entered into the circulation
from the stem cell compartment in the transplanted mice, the
Jak2V617F allele and BLI levels soon returned to high level. The
maintenance of steady level of BLI and allele in the Jak2V617F–Luc2
mice over long period of time suggests that the more primitive
Jak2V617F cell population persisted in the mutant mice, which
continued to be the source of newly differentiated cells, resulting in
sustained high level of BLI and Jak2V617F allele.
To better understand the mechanism for the mutant JAK2-driven
disease in vivo, we introduced a mutant Jak2 carrying a point
mutation in the ATP binding loop, resulting in substitution of lysine
for glutamic acid at amino acid residue 882 [30,31] that abolishes the
kinase activity of Jak2 into the mouse. We show that in contrast to the
Jak2V617F mice that robustly developed PV-like disease, the
Jak2K882E mice did not show PV phenotype. This ﬁnding supports
the previous reports indicating the importance of the kinase activity of
Jak2 in the pathogenesis of PV.
Although it was postulated that one of the cellular events during
the development of PV is skewed cell differentiation, the underlying
molecular mechanism remains obscure. We attempted to examine
several genes important in processes by which the hematopoietic
stem cells differentiate into different lineages in the mouse spleen
where the increased erythropoiesis is predominant. We show that
Sca1, a marker in hematopoietic stem cells [21,22], is highly up-
regulated in the spleen of Jak2V617F mice compared to Jak2WT
control animals. Furthermore, the transcription factor PU.1 [18–20]
that is critical in directing cells into myeloid lineage was down-
regulated in the Jak2V617F mice. On the contrary, the erythroid
transcription factor GATA-1 [15–17] was slightly up-regulated in the
spleens from the Jak2V617F mutant animals. Furthermore, the
erythroid progenitor cells were dramatically increased in the
Jak2V617F mutant mice. These ﬁndings are consistent with a recent
report showing differential transcriptional regulation of the GATA-1
and PU.1 transcription factors in a human cell system [11]. These data
suggest that the overwhelming overproduction of erythroid lineage
cells in the spleen may be at least in part due to perturbed balancebetween myeloid and erythroid cell differentiation processes. Loss of
function analysis of Stat5 has demonstrated a critical role of Stat5 in
hematopoiesis. Effective activation of Stat5 was shown to be
important in hematopoietic stem cell renewal [23,24]. Consistent
with several previous reports [4,6,7], we show that the Jak2V617F
mutation resulted in constitutive activation of Stat5. Interestingly, in
addition to the elevated phosphorylation of the full-length Stat5 in the
Jak2V617F mutant mice, we observed a smaller phosphorylated Stat5
protein, which was only detected in the splenocytes isolated from
Jak2V617F mutant but not Jak2WT mice. It was previously reported
that there are two isoforms of Stat5 due to serine-dependent
proteolysis [27]. The shorter form, termed Stat5β, is a truncated
form of the full-length Stat5 (termed Stat5α) that lacks the COOH-
terminal sequence of Stat5α. Earlier studies demonstrated that the
truncated version of Stat5 serves as a marker in undifferentiated cells
and this truncated protein was not detected in differentiated cells
[25–27]. It has been suggested that the truncated Stat5may play a role
in blocking differentiation and promoting survival. In addition, the
majority of acute myeloid leukemia patients carry the Stat5β isoform
in their hematopoietic tissues and the presence of this isoform is
associated with disease progression [27,32]. While in myeloid
progenitor cell lineages, several cytokines can activate the shorter
form of Stat5, in differentiated mature myeloid cells only the full-
length Stat5 is activated [25,33]. Therefore, our observation of the
activation of the shorter form of Stat5 is intriguing and the fact that
this activation is only detected in the Jak2V617F mutant but not in the
Jak2WT cells under identical sample preparation conditions suggests
that the Jak2V617F mutation predisposes cells to a more undifferen-
tiated state. Taken together, these observations suggest that
Jak2V617F mutation caused imbalanced transcriptional program and
increased stem cell renewal activity, which resulted in impaired cell
differentiation, leading to overproduction of erythroid lineage cells in
the spleen.
In summary, such a model proved to be a very useful system to
study the mechanism and kinetics of PV and may be used as a
preclinical animal model to characterize novel JAK2 inhibitors.
Evaluation of the JAK2 inhibitors will be greatly enhanced by the
non-invasive real-time quantiﬁcation of the disease burden using a
BLI-based assay in the living animals.
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